SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 221 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 1.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $27,067,000 | -11.7% | 817,982 | -6.5% | 0.10% | -15.0% |
| Q1 2019 | $30,663,000 | -2.0% | 875,080 | -7.1% | 0.12% | -15.5% |
| Q4 2018 | $31,277,000 | -30.1% | 941,530 | +6.0% | 0.14% | -20.2% |
| Q3 2018 | $44,717,000 | -19.3% | 888,126 | -4.0% | 0.18% | -25.5% |
| Q2 2018 | $55,386,000 | +29.2% | 925,409 | -1.1% | 0.24% | +17.2% |
| Q1 2018 | $42,862,000 | +9.1% | 935,845 | -5.1% | 0.20% | +9.1% |
| Q4 2017 | $39,294,000 | -6.0% | 986,033 | -5.6% | 0.19% | -6.0% |
| Q3 2017 | $41,787,000 | +6.7% | 1,044,672 | +15.0% | 0.20% | +4.2% |
| Q2 2017 | $39,163,000 | +25.6% | 908,643 | -8.8% | 0.19% | +15.8% |
| Q1 2017 | $31,186,000 | +13.1% | 996,362 | -8.8% | 0.16% | +6.5% |
| Q4 2016 | $27,578,000 | -15.0% | 1,092,211 | -16.8% | 0.16% | -14.4% |
| Q3 2016 | $32,462,000 | +17.9% | 1,312,642 | -2.9% | 0.18% | +17.5% |
| Q2 2016 | $27,544,000 | – | 1,352,162 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |